Companies similar to BridgeBio Pharma, Inc. (BBIO)
Health Care · Nasdaq
BridgeBio Pharma, Inc. (BBIO)'s closest peers include Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN), SCHOLAR ROCK HOLDING CORP (SRRK), ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) and Ultragenyx (RARE). This peer set is drawn from BBIO's enriched company profile and is informational only — not financial advice.
Similar companies
-
Ionis PharmaceuticalsIONSHealth Care
Pioneer in RNA-targeted antisense medicines with seven commercialized products and expanding late-stage pipeline across rare neurological and cardiometabolic…
$54.65 (as of 2026-07-16) · market cap $9.0B
-
Regeneron PharmaceuticalsREGNHealth Care
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic…
$678.94 (as of 2026-07-16) · market cap $70.5B
-
SCHOLAR ROCK HOLDING CORPSRRKHealth Care
Scholar Rock develops myostatin-inhibiting monoclonal antibodies to treat rare neuromuscular diseases like spinal muscular atrophy, with lead candidate…
$51.73 (as of 2026-07-16) · market cap $6.2B
-
ARCTURUS THERAPEUTICS HOLDINGS INCARCTHealth Care
Arcturus Therapeutics develops self-amplifying mRNA therapeutics and vaccines, with the first approved sa-mRNA COVID vaccine (KOSTAIVE) generating revenue…
$6.18 (as of 2026-07-16) · market cap $175M
-
UltragenyxRAREHealth Care
A biopharmaceutical company developing and commercializing novel therapies for rare and ultra-rare genetic diseases with high unmet medical need.
$30.22 (as of 2026-07-16) · market cap $3.1B
Not quite? Describe exactly what you want →
Peers are drawn from BBIO's enriched profile (the same similarity signal the chat uses for "companies like BBIO"). See the full profile: BridgeBio Pharma, Inc. (BBIO).
Last updated 2026-07-16.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.